🇺🇸 FDA
Patent

US 9611230

1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease

granted A61PA61P1/16A61P11/00

Quick answer

US patent 9611230 (1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease) held by PTC THERAPEUTICS, INC. expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61P, A61P1/16, A61P11/00, A61P13/12, A61P19/00